NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/21/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization525.59 mln
Float141 mln
Earnings Date11/05/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
13.25
Transformational upside
Relative Strength
90
/ 100
Top performer
Debt / Equity
0.12
Very low leverage
ROE
-122
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Cabaletta Bio is a Philadelphia-based clinical-stage company developing specialized cell therapies designed to treat a broad range of autoimmune diseases. Its most advanced treatment, resecabtagene autoleucel, is being tested in clinical trials across more than ten conditions, including lupus, multiple sclerosis, and myasthenia gravis, while two additional therapies target specific forms of the skin disorder pemphigus vulgaris and a muscle-weakening antibody-driven disease. The company works alongside leading research institutions and biotech partners to advance its pipeline, and has operated under its current name since 2018.
